Glenmark Pharmaceuticals is introducing travoprost ophthalmic solution, 0.004% (ionic buffered solution), which is the ...

Glenmark’s travoprost ophthalmic solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z ophthalmic solution USP, 0.004% of Sandoz, Inc. According ...

According to the company, the approval has been granted to market a generic equivalent to the reference listed drug (RLD) Travatan Z Ophthalmic Solution, 0.004 percent, of Sandoz Inc. The product ...

Glenmark Pharmaceuticals Inc, USA on Wednesday said it has launched Travoprost ophthalmic solution used in the treatment of ...

Glenmark Pharmaceuticals Inc., USA is pleased to announce the launch of Travoprost Ophthalmic Solution USP, 0.004% (Ionic ...

Glenmark Pharmaceuticals launches a generic glaucoma treatment, Travoprost ophthalmic solution, bioequivalent to Travatan Z.

Travoprost Ophthalmic Solution USP, 0.004%, is used to lower intraocular pressure in patients with ocular hypertension or ...

Glenmark Pharmaceuticals has announced that its U.S. based subsidiary, Glenmark Pharmaceuticals Inc., USA, has launched Travoprost Ophthalmic Solution USP (Ionic Buffered Solution) in the U.S. market.

Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z2 Ophthalmic Solution USP, 0.004% of Sandoz, Inc.

According to IQVIA TM sales data for the 12-month period ending September 2024, the Travatan Z Ophthalmic Solution USP, 0.004% market 3 achieved annual sales of approximately $66.2 million.